Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
2020-11-16
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and the best dose of v-akt murine thymoma
viral oncogene homolog (Akt)/mitogen-activated protein kinase 1(ERK) inhibitor ONC201 and to
see how well it works in treating patients with non-Hodgkin's lymphoma that has returned
after a period of improvement or does not respond to treatment. Akt/ERK inhibitor ONC201 may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.